MCA
ALXN

Morris Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Morris Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,550
Closed -$2.12M – 61
2020
Q4 		$2.12M Sell
13,550
-1,027
-7% -$132K 1.74% 26
2020
Q3 		$1.67M Sell
14,577
-1,193
-8% -$129K 1.47% 26
2020
Q2 		$1.77M Sell
15,770
-592
-4% -$62.9K 1.6% 25
2020
Q1 		$1.47M Buy
16,362
+7,322
+81% +$719K 1.57% 25
2019
Q4 		$978K Sell
9,040
-9,838
-52% -$1.05M 0.82% 30
2019
Q3 		$1.85M Sell
18,878
-747
-4% -$84.2K 1.62% 29
2019
Q2 		$2.57M Sell
19,625
-1,692
-8% -$218K 2.14% 19
2019
Q1 		$2.88M Buy
21,317
+4,803
+29% +$597K 2.26% 22
2018
Q4 		$1.61M Sell
16,514
-7,053
-30% -$834K 1.37% 30
2018
Q3 		$3.28M Sell
23,567
-98
-0.4% -$12.3K 2.19% 23
2018
Q2 		$2.94M Buy
23,665
+1,609
+7% +$188K 2.06% 27
2018
Q1 		$2.46M Buy
22,056
+1,872
+9% +$224K 1.63% 28
2017
Q4 		$2.41M Buy
+20,184
New +$2.46M 1.58% 29

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morris Capital Advisors's ALXN Position: Q1 2021 in Review

Morris Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 13,550 shares — an estimated $2.12M sold.

Morris Capital Advisors first reported a position in ALXN in Q4 2017 and held it in 13 quarters. The position peaked at $3.28M in Q3 2018. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Morris Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Morris Capital Advisors sold 13,550 Alexion Pharmaceuticals shares in Q1 2021, an estimated $2.12M.
  • Morris Capital Advisors first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 13 quarters.
  • Morris Capital Advisors's Alexion Pharmaceuticals position peaked at $3.28M in Q3 2018.
  • 752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Morris Capital Advisors's 13F filing for Q1 2021, filed 16 Apr 2021.